Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad ABLTS:0R44 79 Debt-to-EBITDA is 0.07 as of Jun. 2026, which is 46% below its 10-year median of 0.13. GuruFocus rates LTS:0R44 with a GF Score™ of 79/100 and a GF Value™ of kr33.89 (Fairly Valued). The stock has 4 warning signs investors should review. Among 474 Medical Devices & Instruments companies, C-Rad AB ranks better than 89.03% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for C-Rad AB's Debt-to-EBITDA or its related term are showing as below:
LTS:0R44'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.48 Med: 0.13 Max: 1.83
Current: 0.12
During the past 13 years, the highest Debt-to-EBITDA Ratio of C-Rad AB was 1.83. The lowest was -0.48. And the median was 0.13.
LTS:0R44's Debt-to-EBITDA is ranked better than 89.03% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs LTS:0R44: 0.12
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
C-Rad AB Debt-to-EBITDA Related Terms
C-Rad AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, C-Rad AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
C-Rad AB (LTS:0R44) has a Debt-to-EBITDA of 0.07 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on C-Rad AB. This is 46% below median its historical median of 0.13. According to the industry distribution chart, C-Rad AB ranks #52 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 11%.
Is C-Rad AB's Debt-to-EBITDA too high?
C-Rad AB's current Debt-to-EBITDA of 0.07 is 46% below median its 10-year median of 0.13. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. C-Rad AB's value of 0.07 is 95.7% below this industry median. Based on the distribution chart, C-Rad AB ranks #52 out of 474 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, C-Rad AB has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #52 out of 474 companies for Debt-to-EBITDA. This places C-Rad AB in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.63. C-Rad AB's value of 0.07 is 95.7% below this benchmark. While the company's 10-year median is 0.13 vs. the industry median of 1.63, C-Rad AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Debt-to-EBITDA of 0.07 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on C-Rad AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Debt-to-EBITDA is 0.07, which is 46% below median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.89, compared to a current price of kr36.00 — trading 6.2% above its estimated fair value. The current Debt-to-EBITDA is 0.07, which is 46% below median its 10-year median of 0.13 and 95.7% below the Medical Devices & Instruments industry median of 1.63. C-Rad AB's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Debt-to-EBITDA is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr36.00 is trading 6.2% above its estimated GF Value™ of kr33.89.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
Debt-to-EBITDA: 0.07 (46% below median its 10-year median of 0.13)
GF Value™: kr33.89 vs. price of kr36.00 (6.2% above fair value)
Industry Position: 95.7% below the Medical Devices & Instruments median (#52 of 474)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
79GF Score
Get the complete analysis for LTS:0R44
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
